GlassScriptPhysician profile
Aribbe A Martin
NPI 1437210499
$2,349.66
in general payments reported to CMS, 2019-2025
40 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $140 · 2021: $391 · 2022: $402 · 2023: $320 · 2024: $312 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $421.57 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $228.28 | 2019-2025 | Repatha, Repatha, Evenity |
| Novo Nordisk INC | $210.91 | 2019-2023 | |
| Eisai INC. | $194.75 | 2021-2025 | |
| Abbvie INC. | $158.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $103.69 | 2019-2025 | |
| Biogen, INC. | $97.19 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $88.71 | 2020-2024 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $82.99 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $77.81 | 2019 | |
| Pfizer INC. | $65.40 | 2019-2024 | |
| Dexcom, INC. | $53.44 | 2021-2024 | Dexcom G6 Transmitter |
| Si-Bone, INC. | $36.25 | 2021 | |
| Sunovion Pharmaceuticals INC. | $34.45 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $32.99 | 2023 | Nuedexta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aribbe Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.